Navigating Duchenne treatment: AGAMREE & Catalyst Pathways

Join us for this pre-recorded presentation and Q&A discussing to learn about a new FDA-approved treatment for Duchenne muscular dystrophy. During the session, Catalyst Pharmaceuticals will provide an overview of how this novel corticosteroid works and its efficacy in Duchenne.

You will also learn about the journey to comprehensive support and access through the well-established Catalyst Pathways patient support program.

Recorded Wednesday, November 30, 2023